Synvolux Therapeutics

Synvolux Therapeutics is a Dutch biotechnology company specializing in the development of advanced delivery systems for nucleic acids, proteins, and small molecules. The company's core innovation is the SAINT (Synthetic Amphiphilic Interacting with Nucleotides) technology, a proprietary platform of pyridinium-based cationic lipids designed for high-efficiency intracellular delivery. This technology is utilized to create SAINT-O-Somes, which are stabilized liposomes capable of transporting therapeutic payloads with minimal toxicity and high stability in serum. Synvolux focuses on applying its delivery solutions to gene therapy, DNA and RNA vaccines, and targeted oncology treatments. By offering both research-grade reagents and clinical-grade delivery platforms, the company supports the development of next-generation biopharmaceuticals through strategic partnerships and licensing.